UK markets closed

Will Trevena Continue to Surge Higher?

Zacks Equity Research
Investors need to pay close attention to Intra-Cellular Therapies (ITCI) stock based on the movements in the options market lately.

As of late, it has definitely been a great time to be an investor in Trevena, Inc. TRVN. The stock has moved higher by 31.5% in the past month, while it is also above its 20 Day SMA too. This combination of strong price performance and favorable technical, could suggest that the stock may be on the right path.

We certainly think that this might be the case, particularly if you consider TRVN’s recent earnings estimate revision activity. From this look, the company’s future is quite favorable; as TRVN has earned itself a Zacks Rank #1 (Strong Buy), meaning that its recent run may continue for a bit longer, and that this isn’t the top for the in-focus company. You can see the complete list of today’s Zacks #1 Rank stocks here.

This Could Be the Fastest Way to Grow Wealth in 2019

Research indicates one sector is poised to deliver a crop of the best-performing stocks you'll find anywhere in the market. Breaking news in this space frequently creates quick double- and triple-digit profit opportunities.

These companies are changing the world – and owning their stocks could transform your portfolio in 2019 and beyond. Recent trades from this sector have generated +98%, +119% and +164% gains in as little as 1 month.

Click here to see these breakthrough stocks now >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Trevena, Inc. (TRVN) : Free Stock Analysis Report
To read this article on click here.
Zacks Investment Research